GKWIM
FATE icon

Gerber Kawasaki Wealth & Investment Management’s Fate Therapeutics FATE Stock Holding History

Gerber Kawasaki Wealth & Investment Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10
Closed – – 546
2021
Q3 		$0 Buy
+10
New +$784 ﹤0.01% 1199

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management's FATE Position: Q4 2021 in Review

Gerber Kawasaki Wealth & Investment Management sold out of Fate Therapeutics (FATE) in Q4 2021, closing a stake of 10 shares.

Gerber Kawasaki Wealth & Investment Management first reported a position in FATE in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 250 funds tracked by Wall St. Rank hold FATE as of Q4 2021.

  • Gerber Kawasaki Wealth & Investment Management reported no remaining Fate Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Gerber Kawasaki Wealth & Investment Management sold 10 Fate Therapeutics shares in Q4 2021.
  • Gerber Kawasaki Wealth & Investment Management first reported a position in Fate Therapeutics in Q3 2021 and held it in 1 quarter.
  • Gerber Kawasaki Wealth & Investment Management's Fate Therapeutics position peaked at $0 in Q3 2021.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2021.

Based on Gerber Kawasaki Wealth & Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.